Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

NCT02639351 | Completed Phase 1 Results DMC

• 3 other identifiers: 205496V132_01EXP2014-002430-31
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 years of age).

Conditions

Infections, Meningococcal

Outcome Measures

Primary Outcomes (63)

• Number of Subjects With Any Solicited Local and Systemic Adverse Events (AEs)

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 millimeters (mm) of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature greater than or equal to (≥) 38 degrees Celsius (°C), as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade.

  Within 30 minutes of vaccination (Min) at Day 1

• Number of Subjects With Any Solicited Local and Systemic AEs

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 mm of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature ≥ 38 °C, as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade. Other solicited data included: Analgesic/Antipyretics Use.

  From Day 1 to Day 4 (excluding 30 minutes immediately after vaccination)

• Number of Subjects With Any Solicited Local and Systemic AEs

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 mm of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature ≥ 38 °C, as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade.

  From Day 5 to Day 8

• Number of Subjects With Any Solicited Local and Systemic AEs

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 mm of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature ≥ 38 °C, as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade. Other solicited data included: Analgesic/Antipyretics Use.

  From Day 8 to Day 14

• Number of Subjects With Any Solicited Local and Systemic AEs

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 mm of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature ≥ 38 °C, as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade. Other solicited data included: Analgesic/Antipyretics Use.

  From Day 1 to Day 8 (excluding 30 minutes immediately after vaccination)

• Number of Subjects With Any Solicited Local and Systemic AEs

  Assessed solicited local symptoms were injection site erythema, induration, pain and swelling. Any erythema/induration/swelling = erythema/induration/swelling spreading beyond 25 mm of injection site. Any pain = occurrence of the symptom regardless of intensity grade. Assessed solicited systemic symptoms were arthralgia, chills, diarrhea, fatigue, fever defined as body temperature ≥ 38 °C, as measured orally, headache, loss of appetite, myalgia, nausea, rash, urticaria and vomiting. Any systemic symptom = occurrence of the symptom regardless of intensity grade. Other solicited data included: Analgesic/Antipyretics Use.

  From Day 1 to Day 14 (excluding 30 minutes immediately after any vaccination)

• Number of Subjects With Any Unsolicited AEs

  An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product. This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing conditions. Unsolicited adverse event were defined as symptoms that were not solicited using a Subject Diary and that were spontaneously communicated by a subject who has signed the informed consent. Unsolicited AEs were collected through the Day 29 visit and the analysis was performed for Day 1-29 time frame, instead of Day 1-14 as required by protocol.

  From Day 1 to Day 29

• Number of Subjects With Any Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Study Withdrawal, New Onset of Chronic Disease (NOCDs) and Adverse Events of Special Interest (AESIs).

  SAEs are untoward medical occurrences that at any dose resulted in death,was life-threatening,required/prolonged hospitalization,persistent/significant disability/incapacity,congenital anomaly/in important \& significant medical event that could jeopardize the subject/could required intervention to prevent one of the other outcomes mentioned above.MAAEs are AEs that lead to a visit to a healthcare provider.NOCDs are adverse events that represent new diagnosis of a chronic medical condition that was not present/suspected in a subject prior to study enrolment.AESIs were defined according to MedDRA preferred terms.Certain AESIs are monitored after administration of immunostimulatory agents.These are pre-defined \& include AEs in the SOCs of Gastrointestinal disorders,Liver disorders,Metabolic diseases,Musculo-skeletal disorders,Neuroinflammatory disorders,Skin disorders,Vasculitides \& others.

  From Day 1 to Day 366

• Number of Subjects With Any SAEs, MAAEs, AEs Leading to Study Withdrawal, NOCDs and AESIs.

  SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required or prolonged hospitalization, persistent or significant disability/incapacity, congenital anomaly or in an important and significant medical event that could jeopardize the subject or could requiered intervention to prevent one of the other outcomes mentioned above. MAAEs were defined as an AE that lead to a visit to a healthcare provider. NOCDs were defined as AEs leading to study or vaccine withdrawal. AESIs were defined according to MedDRA preferred terms.Certain AEs of special interest (AESIs) are monitored after the administration of immunostimulatory agents. These are pre-defined and include AEs in the SOCs of Gastrointestinal disorders, Liver disorders, Metabolic diseases, Musculo-skeletal disorders, Neuroinflammatory disorders, Skin disorders, Vasculitides and others

  From Day 1 to Day 29

• Number of Subjects With Any SAEs, MAAEs, AEs Leading to Study Withdrawal, NOCDs and AESIs.

  SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required or prolonged hospitalization, persistent or significant disability/incapacity, congenital anomaly or in an important and significant medical event that could jeopardize the subject or could requiered intervention to prevent one of the other outcomes mentioned above. MAAEs were defined as an AE that lead to a visit to a healthcare provider. NOCDs were defined as AEs leading to study or vaccine withdrawal. AESIs were defined according to MedDRA preferred terms.Certain AEs of special interest (AESIs) are monitored after the administration of immunostimulatory agents. These are pre-defined and include AEs in the SOCs of Gastroin-testinal disorders, Liver disorders, Metabolic diseases, Musculo-skeletal disorders, Neuroinflammatory disorders, Skin disorders, Vasculitides and others

  From Day 29 up to study end (Day 366)

• Absolute Values for Clinical Serum Chemistry Parameters- Sodium (Na), Potassium (K), Chlorine (Cl), Blood Urea Nitrogen (BUN) and Bicarbonate.

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameters: Na, K, Cl, BUN and bicarbonate in millimoles per liter (mmol/L).

  At Day 1 (pre-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameters: Na, K, Cl, BUN and bicarbonate in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameters: Na, K, Cl, BUN and bicarbonate in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameters: Na, K, Cl, BUN and bicarbonate in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Clinical Serum Chemistry Parameters-Creatinine

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameter: Creatinine (CREA) in micro mole per liter (μmol/L)

  At Day 1 (pre-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameter: CREA in μmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameter: CREA in μmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameter: CREA in μmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Clinical Serum Chemistry Parameters- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameters: ALT and AST in International Units per liter (IU/L).

  At Day 1 (pre-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameters: ALT and AST in IU/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameters: ALT and AST in IU/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameters: ALT and AST in IU/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Clinical Serum Chemistry Parameters- C-reactive Protein (CRP)

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameter: CRP in milligram per liter (mg/L).

  At Day 1 (pre-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameters: CRP in mg/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameter: CRP in mg/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Clinical Serum Chemistry Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameter: CRP in mg/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Hematology Parameters- Basophils, Eosniophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Plateletes.

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets in 10\^9 cells per liter (10\^9/L)

  At Day 1 (pre-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets in 10\^9/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets in 10\^9/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameters: basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets in 10\^9/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Hematology Parameters- Red Blood Cells (RBC)

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameter: RBC in 10\^12 cells per liter (10\^12/L).

  At Day 1 (pre-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameter: RBC in 10\^12/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameter: RBC in 10\^12/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameter: RBC in 10\^12/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Hematology Parameters- Hematocrit

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameter: hematocrit in liter per liter (L/L).

  At Day 1 (pre-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameter: hematocrit in L/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameter: hematocrit in L/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameter: hematocrit in L/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Hematology Parameters- Hemoglobin (HGB)

  Analysis was performed on blood samples collected at Day 1 (pre-dose) for the following parameter: HGB in gram per liter (g/L).

  At Day 1 (pre-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 1 (post-dose) for the following parameter: HGB in g/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 8 for the following parameter: HGB in g/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Hematology Parameters

  Analysis was performed on blood samples collected at Day 29 for the following parameter: HGB in g/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Urinalysis Parameters- Urine Erythrocytes (Urine RBC)

  Analysis was performed on urine samples collected at Day 1 (pre-dose) for the following parameter: Urine RBC in microliters (μL).

  At Day 1 (pre-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 1 (post-dose) for the following parameter: Urine RBC in μL. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 8 for the following parameter: Urine RBC in μL. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 results.

  At Day 8

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 29 for the following parameter: Urine RBC in μL. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 results.

  At Day 29

• Absolute Values for Urinalysis Parameters- Urine Glucose

  The absolute value for urinalysis was assessed for the following parameter: urine glucose in mmol/L.

  At Day 1 (pre-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 1 (post-dose) for the following parameter: urine glucose in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 8 (post-dose) for the following parameter: urine glucose in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 8 (post-dose) results.

  At Day 8

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at Day 29 (post-dose) for the following parameter: Urine glucose in mmol/L. The change was calculated as difference between the Day 1 (pre-dose) results and the Day 29 (post-dose) results.

  At Day 29

• Absolute Values for Urinalysis Parameters- Urine Protein

  The absolute value for urinalysis was assessed for the following parameter: urine protein in g/L

  At Day 1 (pre-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at day 1 (post-dose) for the following parameter: urine protein in g/L. The change was calculated as difference between the day 1 (pre-dose) results and the day 1 (post-dose) results.

  At Day 1 (post-dose)

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at day 8 (post-dose) for the following parameter: urine protein in g/L. The change was calculated as difference between the day 1 (pre-dose) results and the day 8 (post-dose) results.

  At Day 8

• Changes in Urinalysis Parameters

  Analysis was performed on urine samples collected at day 29 (post-dose) for the following parameter: urine protein in g/L. The change was calculated as difference between the day 1 (pre-dose) results and the day 29 (post-dose) results.

  At Day 29

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were classified by the investigator as Normal (a value either low or high at baseline and normal post-baseline), High (a value either normal or low at baseline and high post-baseline), Low (a value either normal or high at baseline and low post-baseline) and No change.

  At Day 1 (post-dose)

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were classified by the investigator as Normal (a value either low or high at baseline and normal post-baseline), High (a value either normal or low at baseline and high post-baseline), Low (a value either normal or high at baseline and low post-baseline) and No change.

  At Day 8

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were classified by the investigator as Normal (a value either low or high at baseline and normal post-baseline), High (a value either normal or low at baseline and high post-baseline), Low (a value either normal or high at baseline and low post-baseline) and No change.

  At Day 29

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were defined following the FDA CBER Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" dated September 2007, or the institution's normal ranges if they differ from CBER guidance

  At Day 1 (post-dose)

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were defined following the FDA CBER Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" dated September 2007, or the institution's normal ranges if they differ from CBER guidance

  At Day 8

• Number of Subjects With Abnormal Laboratory Parameter Values

  The abnormal laboratory parameters values were defined following the FDA CBER Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" dated September 2007, or the institution's normal ranges if they differ from CBER guidance

  At Day 29

• Human Complement Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup C (MenC)

  The antibody concentrations were assessed by hSBA directed against MenC serogroup and expressed as GMTs.

  At Day 1 (pre-dose)

• hSBA GMTs Against N. Meningitidis Serogroup C (MenC)

  The antibody concentrations were assessed by hSBA directed against MenC serogroup and expressed as GMTs.

  At Day 29

• Geometric Mean Ratio (GMR) of the Titers of Antibodies Measured by hSBA Against MenC Serogroup

  GMR of GMTs of antibodies against MenC was evaluated at Day 29 relative to Day 1 (pre-dose).

  At Day 29

Secondary Outcomes (5)

• hSBA GMTs Against N. Meningitidis Serogroup C (MenC)

  At Day 8 and Day 181

• GMR of the GMTs of Antibodies Measured by hSBA Against MenC Serogroup

  At Day 8 and Day 181

• Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroup C (MenC).

  At Day 8, Day 29 and Day 181

• Concentrations of Antibodies Against MenC Serogroup Measured by Enzyme Linked Immunosorbent Assay (ELISA)

  At Day 1 (pre-dose), Day 8, Day 29 and Day 181

• Percentage of Subjects With at Least a 4-fold Increase in Antibody Concentrations to MenC as Measured by ELISA

  At Day 8, Day 29 and Day 181

Study Arms (5)

LHD153R Formulation 1 Group

EXPERIMENTAL

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.

Biological: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R

LHD153R Formulation 2 Group

EXPERIMENTAL

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.

Biological: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R

LHD153R Formulation 3 Group

EXPERIMENTAL

Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.

Biological: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R

LHD153R Formulation 4 Group

EXPERIMENTAL

Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.

Biological: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R

MenC Group

ACTIVE COMPARATOR

Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.

Biological: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)

Interventions

Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R BIOLOGICAL

Intramuscular (IM) vaccination of 1 dose of 0.5 mL

LHD153R Formulation 1 Group

Investigational MenC-CRM adjuavnted with 25 ug of LHD153R BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

LHD153R Formulation 2 Group

Investigational MenC-CRM adjuavnted with 50 ug of LHD153R BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

LHD153R Formulation 3 Group

Investigational MenC-CRM adjuavnted with 100 ug of LHD153R BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

LHD153R Formulation 4 Group

Meningococcal C-CRM Conjugate Vaccine (MenC-CRM) BIOLOGICAL

IM vaccination of 1 dose of 0.5 mL

MenC Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female individuals of 18 through 45 years of age on the day of informed consent
• Healthy volunteers with good physical and mental health status, determined on the basis of the medical history, a physical examination and the results of the screening tests as judged by the investigator
• Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
• Individuals who can comply with study procedures including follow-up
• Individuals that are able to understand, read and write German language
• Females of childbearing potential who are using an effective birth control method which they intend to use for at least 30 days after the study vaccination.

You may not qualify if:

• Progressive, unstable or uncontrolled clinical conditions
• Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study
• Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
• Abnormal function of the immune system
• Received immunoglobulins or any blood products within 180 days prior to informed consent
• Received an investigational or non-registered medicinal product within 30 days prior to informed consent or intend to participate in another clinical study at any time during the conduct of this study
• Vulnerable subjects (e.g. persons kept in detention), study personnel or an immediate family or household member of study personnel, subjects with legal incapacity or limited legal capacity
• Any relevant deviation from the laboratory parameters at screening as judged by the investigator
• Previously received any vaccine that included a MenC antigen
• Previously suspected or confirmed disease caused by N. meningitides
• Had household contact with and/or intimate exposure to an individual with culture proven MenC
• A positive serum or urine pregnancy test prior to the study vaccine administration or are currently lactating.
• A positive drugs-of-abuse test prior to the study vaccine administration;
• Received any other vaccines within 30 days prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the administration of study vaccines
• Any other condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Berlin, 14050, Germany

Location

Related Publications (2)

• Siena E, Schiavetti F, Borgogni E, Taccone M, Faenzi E, Brazzoli M, Aprea S, Bardelli M, Volpini G, Buricchi F, Sammicheli C, Tavarini S, Bechtold V, Blohmke CJ, Cardamone D, De Intinis C, Gonzalez-Lopez A, O'Hagan DT, Nuti S, Seidl C, Didierlaurent AM, Bertholet S, D'Oro U, Medini D, Finco O. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. Vaccine. 2023 Jan 16;41(3):724-734. doi: 10.1016/j.vaccine.2022.12.006. Epub 2022 Dec 21.

  PMID: 36564274 DERIVED

• Gonzalez-Lopez A, Oostendorp J, Koernicke T, Fadini T, D'Oro U, Baker S, O'Hagan DT, Del Giudice G, Siena E, Finco O, Medini D. Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clin Immunol. 2019 Dec;209:108275. doi: 10.1016/j.clim.2019.108275. Epub 2019 Oct 24.

  PMID: 31669193 DERIVED

MeSH Terms

Conditions

Meningococcal Infections

Condition Hierarchy (Ancestors)

Neisseriaceae Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

kt144805@gsk.com

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 21, 2015
• First Posted: December 24, 2015
• Study Start: March 1, 2016
• Primary Completion: August 31, 2017
• Study Completion: August 31, 2017
• Last Updated: June 28, 2019
• Results First Posted: June 7, 2019

Record last verified: 2019-06

Locations

DE (1)